Vesilute
Vesilute is a synthetic dipeptide bioregulator (Lys-Glu) developed by the Khavinson group that modulates gene expression, promotes smooth muscle relaxation, and improves microcirculation. It is primarily investigated for its potential therapeutic applications in bladder and prostate health.
Vesilute is a Khavinson bioregulator dipeptide consisting of glutamic acid and aspartic acid (ED), developed at the St. Petersburg Institute of Bioregulation and Gerontology. It is specifically designed to support bladder and urinary tract function, with research indicating potential benefits for prostate health in men. Vesilute may help regulate smooth muscle function, enhance tissue blood flow, and support cellular regeneration in urogenital tissues. It is distinct from Vesugen (KED tripeptide), which targets vascular endothelium.
Mechanism of Action
Vesilute acts on the smooth muscle cells and vascular endothelium of the urogenital system. It is proposed to: (1) regulate smooth muscle contraction and relaxation in the bladder wall, (2) enhance microcirculation and blood flow in pelvic tissues including prostate, (3) support cellular regeneration and tissue repair in the urinary tract, (4) reduce hyperemia and inflammation-related dysfunction, and (5) modulate gene expression related to urogenital tissue homeostasis through bioregulation pathways characteristic of Khavinson peptides.
Safety Profile
Safety Profile: Vesilute
Common Side Effects
- Injection site reactions: redness, swelling, and mild pain
- Mild fatigue and malaise
- Headache
- Mild gastrointestinal discomfort
Serious Adverse Effects
- Very limited published safety data; Vesilute is a short peptide bioregulator (Lys-Glu dipeptide derivative) from the Khavinson peptide series
- Allergic reactions (theoretical, as with all injectable peptides)
- No well-documented serious adverse events in available literature, but absence of evidence is not evidence of absence
- Long-term effects unknown
Contraindications
- Known hypersensitivity to Vesilute or related peptide bioregulators
- Pregnancy and lactation (no safety data)
- Children (no pediatric data)
- Active autoimmune conditions (immune-modulating properties)
Drug Interactions
- Immunosuppressants: May interfere with immunosuppressive therapy due to immune-modulating effects
- Other peptide bioregulators: Often used in combination in the Khavinson protocol; interactions between multiple bioregulator peptides are unstudied
- No well-characterized CYP450 or transporter interactions
Population-Specific Considerations
- Primarily available in Russia: Limited availability and regulatory oversight outside Russia/CIS countries
- Immune system focus: Proposed to support bladder and urinary tract mucosal immunity
- Elderly population: Primary target demographic in peptide bioregulator protocols
- Evidence quality: Most published research is from Russian-language journals with limited peer review by international standards
- Combination protocols: Often used alongside other Khavinson peptides (Epithalon, Thymalin); combined safety is uncharacterized
Pharmacokinetic Profile
- Half-life
- Not established
Quick Start
- Typical Dose
- 10-20 mg per day
- Frequency
- Daily for 10-20 consecutive days (Khavinson bioregulator cycle)
- Cycle Length
- 10-20 day cycle
- Storage
- Lyophilized powder: room temperature or 2-8°C; Reconstituted: 2-8°C refrigerated, use within 4 weeks
Molecular Structure
- Weight
- 262 Da
- Length
- 2 amino acids
Research Indications
Urinary Tract Health
Research explores relief of symptoms associated with bladder dysfunction through smooth muscle regulation.
May support overall urinary tract function and tissue health.
Potential benefits for pelvic tissue health and function.
Prostate Health (Men)
Research indicates potential to enhance blood flow and reduce dysfunction in prostate tissue.
May help alleviate symptoms associated with benign prostatic hyperplasia.
Anti-Aging Protocol
Part of comprehensive bioregulator protocols addressing age-related urogenital changes.
Supports cellular regeneration in urinary and reproductive tissues.
Research Protocols
subcutaneous Injection
Injectable form for subcutaneous or intramuscular administration. Standard Khavinson protocol of 10-20 day cycles, repeated 2-3 times per year for maintenance.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Standard protocol | 10-20 mg | Daily for 10-20 days | —(Route: SubQ or IM) |
| Maintenance | 20 mg | 2-3 cycles yearly | —(Route: SubQ or IM) |
Reconstitution Guide (mg vial + mL BAC water)
- Clean work area thoroughly
- Reconstitute with bacteriostatic water
- Inject water slowly down vial wall
- Gently swirl until dissolved
- Store refrigerated at 2-8°C
- Use within 4 weeks of reconstitution
oral
Oral capsule form may be available. As a small dipeptide, Vesilute has reasonable oral bioavailability.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Oral protocol | 10-20 mg | Daily for 10-20 days | —(Route: Oral capsules) |
Interactions
Peptide Interactions
Both target prostate/urogenital health; can be combined for comprehensive support.
Different targets - Vesugen for vascular, Vesilute for bladder/prostate. Can be combined.
Often combined in comprehensive anti-aging bioregulator protocols.
Different target systems; no known negative interactions.
What to Expect
What to Expect
Tissue-specific effects begin; gene expression modulation
Cellular function optimization in target tissues
Effects persist due to bioregulation mechanisms
Cumulative benefits with regular cycling; tissue health maintenance
Safety Profile
Common Side Effects
- Generally well-tolerated
- Injection site reactions (mild, if injectable)
- Minimal reported side effects
Contraindications
- Known hypersensitivity to peptide components
- Active urinary tract infection (treat first)
- Pregnancy or breastfeeding
- Prostate cancer (consult physician)
Discontinue If
- Signs of allergic reaction
- Unusual urinary symptoms
- Unexpected changes in urination patterns
Quality Indicators
What to look for
- White to off-white lyophilized powder
- Clear solution after reconstitution
- Certificate of analysis available
- Proper packaging and storage
Caution
- Unknown source or unverified purity
Red flags
- Discolored powder
- Cloudy or particulate solution
- Damaged packaging
References (3)
- [1]Khavinson Bioregulator Peptides: Organ-Specific Effects
- [2]Short Peptides and Urogenital Function
- [3]Bioregulators in Anti-Aging Medicine
Ventfort
Ventfort is a complex peptide preparation classified as a cytomedine — a tissue-specific bioregulator developed at the St. Petersburg Institute of Bioregulation
Vesugen
Vesugen is a Khavinson bioregulator tripeptide developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology. Composed of three amino acids (l